Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Balslev

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 3, 2021
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast CancerElisabeth S Stovgaard, Iben Kümler, Kamille List-Jensen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|September 16, 2011
High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancerLene Rask, Eva Balslev, Stine Jørgensen, et al.
Breast Cancer Research and Treatment|December 25, 2007
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancerAnne Roslind, Ann S Knoop, Maj-Britt Jensen, et al.
Acta Oncologica (Stockholm, Sweden)|October 11, 2015
Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancersTove F Tvedskov, Maj-Britt Jensen, Eva Balslev, et al.
Molecular Oncology|December 14, 2011
Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A statusKirsten Vang Nielsen, Bent Ejlertsen, Susanne Møller, et al.
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
Frontiers in Oncology|September 2, 2014
miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast CancerBoye Schnack Nielsen, Eva Balslev, Tim Svenstrup Poulsen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 29, 2020
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer PatientsSofie S Jespersen, Elisabeth S Stovgaard, Dorte Nielsen, et al.
BMC Cancer|June 3, 2014
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative groupCharlotte Levin Tykjær Jørgensen, Christina Bjerre, Bent Ejlertsen, et al.
BMC Medical Genomics|June 11, 2009
Identification and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencingSanne Nygaard, Anders Jacobsen, Morten Lindow, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 3, 2021
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast CancerElisabeth S Stovgaard, Iben Kümler, Kamille List-Jensen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|September 16, 2011
High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancerLene Rask, Eva Balslev, Stine Jørgensen, et al.
Breast Cancer Research and Treatment|December 25, 2007
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancerAnne Roslind, Ann S Knoop, Maj-Britt Jensen, et al.
Acta Oncologica (Stockholm, Sweden)|October 11, 2015
Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancersTove F Tvedskov, Maj-Britt Jensen, Eva Balslev, et al.
Molecular Oncology|December 14, 2011
Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A statusKirsten Vang Nielsen, Bent Ejlertsen, Susanne Møller, et al.
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
Frontiers in Oncology|September 2, 2014
miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast CancerBoye Schnack Nielsen, Eva Balslev, Tim Svenstrup Poulsen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 29, 2020
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer PatientsSofie S Jespersen, Elisabeth S Stovgaard, Dorte Nielsen, et al.
BMC Cancer|June 3, 2014
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative groupCharlotte Levin Tykjær Jørgensen, Christina Bjerre, Bent Ejlertsen, et al.
BMC Medical Genomics|June 11, 2009
Identification and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencingSanne Nygaard, Anders Jacobsen, Morten Lindow, et al.
Pageof 9